Steam-cooking rapidly destroys and reverses onion-induced antiplatelet activity

Emilie A Hansen1, John D Folts, Irwin L Goldman

  • 1Department of Horticulture, University of Wisconsin-Madison, 1575 Linden Drive, Madison, WI 53706, USA.

Nutrition Journal
|September 21, 2012
PubMed
Abstract

Insights

Steaming onions for 3-6 minutes destroys their anti-platelet activity, while longer steaming times can reverse this effect. Polyphenol concentration remains unaffected by cooking time.

Area of Science:

  • Food Science
  • Pharmacology
  • Nutritional Science

Background:

  • Dietary foods with disease-preventive properties are of significant interest.
  • Onions, a global culinary staple, exhibit anti-platelet aggregation properties.
  • Heating, such as boiling, may abolish the anti-platelet activity of onions.

Purpose of the Study:

  • To investigate the impact of steaming duration on the in vitro anti-platelet activity of onions.
  • To determine how cooking affects the pharmacological properties of onions related to blood platelets.

Main Methods:

  • Onion quarters were steamed for varying durations (0-15 minutes).
  • In vitro anti-platelet activity was assessed using whole blood aggregometry on human blood samples.
  • Total polyphenolic concentration and soluble solids were measured.

Main Results:

  • Anti-platelet activity was lost between 3 and 6 minutes of steaming.
  • Steaming for 10 minutes led to stimulation of platelet activity.
  • Cooked onion extracts reversed inhibitory effects on blood platelets by 25% without altering polyphenol content.

Conclusions:

  • Steaming onions can lead to the destruction or reversal of anti-platelet activity.
  • The polyphenolic concentration in onions is not significantly affected by steaming time.
  • Cooked onion preparations may have complex effects on blood platelet function.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Inflammation01:38

Inflammation

Overview
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...